DelveInsight’s Major Depressive Disorder Market Insights report provides a thorough understanding of current treatment practices, emerging drugs, Major Depressive Disorder market share of the individual therapies, current and forecasted Major Depressive Disorder market size from 2018 to 2030 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).
Major Depressive Disorder Overview
Major depressive disorder (MDD) is one of the most prevalent psychiatric disorders and has been projected by the World Health Organization to be the leading cause of disease burden in high-income countries by 2032. It is characterized by persistent sadness, loss of interest or pleasure, low energy, worse appetite and sleep and even suicide, disrupting daily activities and psychosocial functions.
Download sample report @ https://www.delveinsight.com/sample-request/major-depressive-disorder-market
Some of the key features of the Major Depressive Disorder Market Report
According to the available literature, MDD is more common in females than in males.
Major depressive disorder is a highly prevalent psychiatric disorder. It has a lifetime prevalence of about 5 to 17 percent, with the average being 12 percent.
Estimated that Major Depressive Disorder affects 322 million people globally, representing an 18.4% increase in the number of people living with Major Depressive Disorder between 2005 and 2015.
Major Depressive Disorder companies are included like Takeda Pharmaceuticals, Forest Laboratories, Otsuka Pharmaceuticals, Janssen Research & Development, Axsome Therapeutics, Fabre-Kramer Pharmaceuticals, SAGE Therapeutics, and several others.
Major Depressive Disorder therapies are included like Brintellix, Fetzima, Pharmacokinetics, Rexulti, SPRAVATO (Esketamine), and several others.
Major Depressive Disorder Diagnosis
It is diagnosed when an individual has a persistently low or depressed mood, anhedonia or decreased interest in pleasurable activities, feelings of guilt or worthlessness, lack of energy, poor concentration, appetite changes, psychomotor retardation or agitation, sleep disturbances, or suicidal thoughts. As per the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5), an individual must have five of the above-mentioned symptoms, of which one must be a depressed mood or anhedonia causing social or occupational impairment, to be diagnosed with MDD.
Feelings of sadness, tearfulness, emptiness or hopelessness.
Angry outbursts, irritability or frustration, even over small matters.
Loss of interest or pleasure in most or all normal activities, such as sex, hobbies or sports.
Sleep disturbances, including insomnia or sleeping too much.
Major Depressive Disorder Treatment
The treatment strategies for depression consists of pharmacological and non-pharmacological options, including psychotherapy, electroconvulsive therapy, and transcranial magnetic stimulation. In recent years, psychotherapy has been shown to affect depression, including attenuating depressive symptoms and improving quality of life. Therefore, several practice guidelines are increasingly recommending psychotherapy as a monotherapy or in combination with antidepressants.
Major Depressive Disorder Epidemiology Segmentation in the 7MM
12 Months Prevalent Cases
Major Depressive Disorder Market Insights
In cases of MDD severity, if it is determined to be mild to moderate, the initial treatment consists of an evidence-based mono-therapy. Mild symptoms may be relieved by learning about the condition, lifestyle changes (such as regular physical exercise), and psychological therapy provided by a mental health professional. For moderate to more severe depression, pharmacological treatments are likely to be required combined with these other treatments.
Get to know more information about the report @ https://www.delveinsight.com/sample-request/major-depressive-disorder-market
Major Depressive Disorder Emerging Therapy Assessment
The dynamics of Major Depressive Disorder market is anticipated to change in the coming years owing to the expected approval of emerging therapies, rising awareness of the disease, and better approaches to therapy development across the world during the forecasted period of 2022‒2032. Currently, there are several emerging therapies focused on the treatment of Major Depressive Disorder that include AXS-05 (Axsome Therapeutics), Zuranolone (SageTherapeutics/Biogen/Shionogi), Vraylar/Cariprazine (Gedeon Richter/AbbVie), and LY03005/Ansofaxine hydrochloride (Luye Pharma Group), among others.
Table of Content
1. Key Insights
2. Executive Summary of Major Depressive Disorder
3. Competitive Intelligence Analysis for Major Depressive Disorder
4. Major Depressive Disorder: Market Overview at a Glance
5. Major Depressive Disorder: Disease Background and Overview
6. Patient Journey
7. Major Depressive Disorder Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Major Depressive Disorder Unmet Needs
10. Key Endpoints of Major Depressive Disorder Treatment
11. Major Depressive Disorder Marketed Products
12. Major Depressive Disorder Emerging Therapies
13. Major Depressive Disorder: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Major Depressive Disorder
17. KOL Views
18. Market Drivers
19. Market Barriers
21. DelveInsight Capabilities
23. About DelveInsight
Get in touch with our Business Expert @ https://www.delveinsight.com/sample-request/major-depressive-disorder-market
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States